Orogen Royalties Inc

Orogen Royalties Inc logo
🇺🇸United States
Ownership
Public
Established
2020-01-01
Employees
10K
Market Cap
-
Website
http://www.organon.com
Introduction

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Clinical Trials
Related News

Desloratadine With Oxybutynin for the Treatment of Seasonal Allergic Rhinitis and Post-Nasal Drip (Study P04258)(COMPLETED)

First Posted Date
2009-01-06
Last Posted Date
2022-02-16
Lead Sponsor
Organon and Co
Target Recruit Count
540
Registration Number
NCT00816972

A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis

Phase 3
Completed
Conditions
Migraine
Interventions
Drug: rizatriptan benzoate
First Posted Date
2008-12-19
Last Posted Date
2024-05-23
Lead Sponsor
Organon and Co
Target Recruit Count
108
Registration Number
NCT00812006

A Study of the Bioequivalence of 70 mg Alendronate and 70 mg Alendronate in Combination With 2800 IU Vitamin D

Phase 1
Completed
Conditions
Osteoporosis
Interventions
Drug: alendronate sodium (+) cholecalciferol
First Posted Date
2008-12-10
Last Posted Date
2022-02-08
Lead Sponsor
Organon and Co
Target Recruit Count
244
Registration Number
NCT00806416

Study of the Effectiveness and Safety of Desloratadine (Aerius) Syrup in Children With Hayfever With or Without Asthma (P03472)

Phase 3
Completed
Conditions
Rhinitis, Allergic, Seasonal
Asthma
Interventions
Drug: Desloratadine
First Posted Date
2008-12-09
Last Posted Date
2022-02-16
Lead Sponsor
Organon and Co
Target Recruit Count
54
Registration Number
NCT00805324

Study of Nasal Symptom Relief and Side Effects in Hayfever Patients Treated With Aerius (Desloratadine)(P03442)

Phase 4
Completed
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Drug: desloratadine
First Posted Date
2008-12-09
Last Posted Date
2022-02-17
Lead Sponsor
Organon and Co
Target Recruit Count
311
Registration Number
NCT00805584

A Study of the Bioequivalence of 70-mg Alendronate and 70-mg Alendronate in Combination With 5600 IU Vitamin D (MK0217A-253)

Phase 1
Completed
Conditions
Osteoporosis
Interventions
Drug: alendronate sodium+vitamin D combination
First Posted Date
2008-12-08
Last Posted Date
2022-02-03
Lead Sponsor
Organon and Co
Target Recruit Count
318
Registration Number
NCT00803790

Montelukast in Chronic Asthma

Completed
Conditions
Asthma
First Posted Date
2008-12-05
Last Posted Date
2022-02-18
Lead Sponsor
Organon and Co
Target Recruit Count
2000
Registration Number
NCT00802789

How Desloratadine (Clarinex, Aerius) Affects Quality of Life in Patients With Chronic Idiopathic Urticaria (Have Had Hives for 6 Weeks or Longer)(Study P02988)

Phase 3
Completed
Conditions
Urticaria
Interventions
Drug: desloratadine
First Posted Date
2008-11-21
Last Posted Date
2022-02-17
Lead Sponsor
Organon and Co
Target Recruit Count
282
Registration Number
NCT00795158

An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria (Study P02540)

Phase 4
Completed
Conditions
Urticaria
Interventions
Drug: Desloratadine
First Posted Date
2008-11-21
Last Posted Date
2022-02-17
Lead Sponsor
Organon and Co
Target Recruit Count
51
Registration Number
NCT00795522

Taste Test Between Desloratadine and Cetirizine Syrup in Children (Study P03829)(COMPLETED)

First Posted Date
2008-11-20
Last Posted Date
2022-02-16
Lead Sponsor
Organon and Co
Target Recruit Count
202
Registration Number
NCT00794378
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy